Literature DB >> 1532927

T and B cell responses following immunization with tetanus toxoid in IgA nephropathy.

F Fortune1, M Courteau, D G Williams, T Lehner.   

Abstract

The B and T cell responses were investigated in IgA nephropathy before and after immunization with tetanus toxoid (TT). Both IgA and IgG anti-tetanus toxoid antibodies were elicited, but the IgA antibodies were significantly greater in patients (92.6 +/- 11.7 ELISA units) than in the controls (49.2 +/- 7.5 ELISA units). This was associated with a significantly greater proportion of IgA+ B cells in patients than controls before immunization. However, a significant increase in the proportion of IgA1 binding CD4 and CD8 cells was also found. The proportion of CD3 cells with gamma delta T cell receptors (CD3+TCR gamma delta +), was significantly greater before immunization in the IgA nephropathy patients (37.0% +/- 2.4), compared with controls (10.0% +/- 2.3; P less than 0.001). Immunization with TT further enhanced the CD3+TCR gamma delta + cells in patients to 45.8% +/- 7.2 compared with controls (16.3% +/- 4.5), with a corresponding decrease in CD3+TCR alpha beta + cells in the patients (P less than 0.001). CD3+TCR gamma delta + cells are upregulated by common microbial antigens and clinical exacerbations of IgA nephropathy are frequently associated with mucosal infections and a rise in serum IgA concentration. The increased TCR gamma delta expression may be responsible for the enhanced IgA antibody response in IgA nephropathy. The increase in IgA antibodies may than exert a controlling effect by binding to augmenting T cells and thereby inhibiting their function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532927      PMCID: PMC1554370          DOI: 10.1111/j.1365-2249.1992.tb03040.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Stimulation of a major subset of lymphocytes expressing T cell receptor gamma delta by an antigen derived from Mycobacterium tuberculosis.

Authors:  R L O'Brien; M P Happ; A Dallas; E Palmer; R Kubo; W K Born
Journal:  Cell       Date:  1989-05-19       Impact factor: 41.582

2.  Decrease of IgA-specific suppressor T cell activity in patients with IgA nephropathy.

Authors:  H Sakai; Y Nomoto; S Arimori
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

3.  Dietary gluten and primary IgA nephropathy.

Authors:  R Coppo; B Basolo; C Rollino; D Roccatello; G Martina; A Amore; G Piccoli
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

4.  Frontiers of the immune system.

Authors:  C A Janeway
Journal:  Nature       Date:  1988-06-30       Impact factor: 49.962

5.  Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera.

Authors:  J M Griffiss
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

6.  IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms.

Authors:  J M Griffiss; D K Goroff
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

7.  T cell hybridomas coexpressing Fc receptors (FcR) for different isotypes. II. IgA-induced formation of suppressive IgA binding factor(s) by a murine T hybridoma bearing Fc gamma R and Fc alpha R.

Authors:  J Yodoi; M Adachi; K Teshigawara; M Miyamainaba; T Masuda; W H Fridman
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

8.  Evidence for IgA-specific B cell hyperactivity in patients with IgA nephropathy.

Authors:  G M Hale; S L McIntosh; Y Hiki; A R Clarkson; A J Woodroffe
Journal:  Kidney Int       Date:  1986-03       Impact factor: 10.612

9.  Identification and characterization of IgA and Vicia villosa-binding T cell subsets in rheumatoid arthritis.

Authors:  F Fortune; J Kingston; C S Barnes; T Lehner
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

10.  Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in an MHC-restricted fashion.

Authors:  D Kozbor; G Trinchieri; D S Monos; M Isobe; G Russo; J A Haney; C Zmijewski; C M Croce
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  9 in total

1.  Expression of T cell receptor variable region families by bone marrow gammadelta T cells in patients with IgA nephropathy.

Authors:  K S Buck; E M Foster; D Watson; J Barratt; I Z A Pawluczyk; J F Knight; J Feehally; A C Allen
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

2.  For further investigations in IgA nephropathy the approach from phenotype to genotype is welcome.

Authors:  F P Schena
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

3.  T-cell epitopes recognized within the 65,000 MW hsp in patients with IgA nephropathy.

Authors:  K Warr; F Fortune; S Namie; A Wilson; T Shinnick; R Van der Zee; G Williams; T Lehner
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

Review 4.  The mucosa-kidney axis in IgA nephropathy.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2015-12-30       Impact factor: 28.314

5.  Analysis of human T-cell receptor V beta gene usage following immunization to tetanus toxoid in vivo.

Authors:  M L Hibberd; F S Wong; L B Nicholson; A G Demaine
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

Review 6.  Immunopathogenesis of IgAN.

Authors:  Jonathan Barratt; Alice C Smith; Karen Molyneux; John Feehally
Journal:  Semin Immunopathol       Date:  2007-09-13       Impact factor: 9.623

7.  A human T-cell receptor recognizes 'O'-linked sugars from the hinge region of human IgA1 and IgD.

Authors:  P M Rudd; F Fortune; T Patel; R B Parekh; R A Dwek; T Lehner
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

Review 8.  Pathogenesis of idiopathic IgA nephropathy.

Authors:  D G Williams
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

Review 9.  Tuberculosis-associated IgA nephropathy.

Authors:  Yamei Wang; Yuhong Tao
Journal:  J Int Med Res       Date:  2018-06-04       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.